About IOMICS
IOMICS is a company based in Cambridge (United States) founded in 2013. It operates as a B2B and SaaS. IOMICS offers products and services including Cures Accelerator and AI Drug Design Tools. IOMICS operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, Predictive Oncology and BigHat, among others.
- Headquarter Cambridge, United States
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website iomics.ai
- Legal Name Iomics Corporation
Products & Services of IOMICS
IOMICS offers a comprehensive portfolio of products and services, including Cures Accelerator and AI Drug Design Tools.
Platform for accelerating drug discovery and research through AI automation.
Tools for identifying drug targets and optimizing chemical species via machine learning.
Competitors of IOMICS
IOMICS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, Predictive Oncology and BigHat, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| owkin.com | 2016 | Paris, France | $321.1M | 47 | An agentic AI platform is developed for biomedical research insights. | |
| formation.bio | 2016 | New York, United States | $608M | – | AI-powered drug discovery platform for various diseases | |
| absci.com | 2011 | Vancouver, United States | $227.56M | 256 | AI-based technology is used for recombinant protein production in therapeutics. | |
| predictive-oncology.com | 2002 | Eagan, United States | $43M | 31 | AI-based platform for cancer diagnostics and precision medicine is utilized. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| benchsci.com | 2015 | Toronto, Canada | $157.73M | – | AI platform used for extracting antibody data from scientific papers. | |
| xtalpi.com | 2014 | Cambridge, United States | $783.5M | 33 | AI-driven crystal structure prediction for pharmaceutical development is offered. | |
| iambic.ai | 2019 | San Diego, United States | $206.23M | 50 | AI-driven drug discovery platform for the treatment of cancer |
Detailed competitors of IOMICS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to IOMICS
10 companies that operate in the same segment as IOMICS (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IOMICS
IOMICS was founded in 2013.
IOMICS is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
IOMICS is a technology company that creates AI-driven platforms for systems and synthetic biology, focusing on drug discovery, repurposing, and polypharmacology. It uses machine learning to accelerate intelligent drug design and precision medicine, integrating with research pipelines. Based in Cambridge, MA, USA, it serves life sciences organizations through services like the Cures Accelerator platform. The company emphasizes data-driven innovation and seamless integration for clients in biotechnology and healthcare.
IOMICS's top competitors include Owkin, Formation Bio and XtalPi.
IOMICS offers Cures Accelerator and AI Drug Design Tools.
IOMICS operates through Iomics Corporation.